Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

However, one industry observer cautions against moving forward with specific GLP-1 claims on packaging until federal agencies ...

Novo has been trying to strengthen its foothold in the potential $150 billion obesity market through the development of ...

Here is Danone North America’s commercial masterstroke laid bare: the food, beverage and nutrition company manages to promote ...

Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.

Research shows that glucagon-like peptide-1 receptor agonists (or GLP-1s – think Ozempic or similar medications) are changing ...

“There’s lots of ways to communicate to a GLP-1 user and anyone wanting to lose weight that the food is healthy, a smaller portion and a great source of protein and fiber. They’ll be able to recognize ...

However, one industry observer cautions against moving forward with specific GLP-1 claims on packaging until federal agencies ...

Biomea Fusion (BMEA) announced the presentation of preclinical and clinical data from studies assessing icovamenib at the Advanced Technologies ...

Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their ...

GLP-1 weight loss drugs cost CT’s Medicaid program $85 million in FY 2024, 35% of annual Medicaid pharmaceutical budget ...